B
Bonaventura Clotet
Researcher at University of Vic
Publications - 861
Citations - 42724
Bonaventura Clotet is an academic researcher from University of Vic. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 94, co-authored 784 publications receiving 39004 citations. Previous affiliations of Bonaventura Clotet include Autonomous University of Barcelona & Foundation University, Islamabad.
Papers
More filters
Update of the Drug Resistance Mutations in HIV-1.
Victoria A. Johnson,F. Brun-Vezinet,Bonaventura Clotet,Huldrych F. Günthard,Daniel R. Kuritzkes,Deenan Pillay,Jonathan M. Schapiro,Douglas D. Richman +7 more
TL;DR: The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group reviews new data on HIV-1 drug resistance that have been published or presented at recent scientific meetings to maintain a current list of mutations associated with antiretroviral drug resistance.
Journal ArticleDOI
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
Alison Rodger,Valentina Cambiano,Tina Bruun,Pietro Vernazza,Simon Collins,Jan van Lunzen,Giulio Maria Corbelli,Vicente Estrada,Anna Maria Geretti,Apostolos Beloukas,David Asboe,Pompeyo Viciana,Félix Gutiérrez,Bonaventura Clotet,Christian Pradier,Jan Gerstoft,Rainer Weber,Katarina Westling,Gilles Wandeler,Jan M. Prins,Armin Rieger,Marcel Stoeckle,Tim Kümmerle,Teresa Bini,Adriana Ammassari,Richard Gilson,Ivanka Krznaric,Matti Ristola,Robert Zangerle,Pia Handberg,Antonio Antela,Sris Allan,Andrew N. Phillips,Jens D Lundgren +33 more
TL;DR: Evaluating the rate of within-couple HIV transmission among serodifferent heterosexual and MSM couples during periods of sex without condoms and when the HIV-positive partner had HIV-1 RNA load less than 200 copies/mL found no phylogenetically linked transmissions.
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
Martin S. Hirsch,Scott M. Hammer,Victoria A. Johnson,Daniel R. Kuritzkes,Clive Loveday,John W. Mellors,Bonaventura Clotet,Brian Conway,Lisa M. Demeter,Stefano Vella,Donna M. Jacobsen,Douglas D. Richman +11 more
TL;DR: Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings, and resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women.
Journal ArticleDOI
Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
Martin S. Hirsch,Françoise Brun-Vézinet,Richard T. D'Aquila,Scott M. Hammer,Victoria A. Johnson,Daniel R. Kuritzkes,Clive Loveday,John W. Mellors,Bonaventura Clotet,Brian Conway,Lisa M. Demeter,Stefano Vella,Donna M. Jacobsen,Douglas D. Richman +13 more
TL;DR: The International AIDS Society-USA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing as discussed by the authors.
Journal ArticleDOI
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Roy M. Gulick,Jacob Lalezari,James Goodrich,Nathan Clumeck,Edwin DeJesus,Andrzej Horban,Jeffrey P. Nadler,Bonaventura Clotet,Anders Karlsson,Michael Wohlfeiler,John B. Montana,Mary Mchale,John F. Sullivan,Caroline E. Ridgway,Steve Felstead,Michael W. Dunne,Elna van der Ryst,Howard Mayer +17 more
TL;DR: Maraviroc, as compared with placebo, resulted in significantly greater suppression of HIV-1 and greater increases in CD4 cell counts at 48 weeks in previously treated patients with R5 HIV- 1 who were receiving OBT.